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Introduction
Undifferentiated pancreatic carcinoma with osteoclast-like
giant cells (UPC-OGCs) is a rare neoplasm with frequency
of 0.2 % of reported pancreatic carcinomas [1]. Tumors
with osteoclast-like giant cells have rarely been reported in
a variety of extra-skeletal sites. On the alimentary tract, the
pancreas is the most concerned [2, 3]. A number of terms have
been used to describe variants of undifferentiated pancreatic
carcinoma, especially pleomorphic carcinoma, pleomorphic
giant cell carcinoma, sarcomatoid carcinoma, spindle cell
carcinoma, anaplastic carcinoma, undifferentiated carcinoma,
and osteoclastic or pleomorphic giant cell tumors [4].
Histologically, the tumor combines two main cell popula-
tions, a malignant mononuclear cells population and the
scattered nonneoplastic osteoclast-like giant cells [3, 5].
Since the first description by Rosai in 1968 [6], there have
been only a few cases reported in the world literature. Our aim
is to describe a new case of undifferentiated carcinoma of the
pancreas with osteoclast-like giant cells which was early
diagnosed, with a review of literature.
Case Report
A 60-year-old woman with no medical history was referred
with upper abdominal pain of five-months duration. She did
not report any weight loss or fever. The physical examination
and vital signs were normal. Her abdomen was soft and
nontender. Serum chemistries were within the normal range
except for a glucose level of 2.7 g/dL. Serum cancer antigen
19–9 was elevated to 62UI/mL (normally lower to 37UI/mL),
and carcinoembryonic cancer antigen was normal. Ultra-
sound examination demonstrated a 2.4-cm well-defined,
hypoechogenous, nodular formation in the pancreatic body
(Fig. 1). Abdominal computed tomography revealed a very
limited tissue mass in the pancreatic body, measuring 2.1×
1.5 cm responsible for dilatation of main pancreatic duct
(5 mm) with upstream pancreatic atrophy (Fig. 2). Surgical
exploration shows a very limited mass in the body of the
pancreas without local invasion, lymph nodes, or other
metastasis. The patient received distal pancreatectomy with
spleen preservation (Fig. 3). She had an uneventful post-
operative recovery. Pathology showed a mixed macroscopic
structure and a diffused tumor proliferation in microscopy.
The tumor cells had moderate to marked cytonuclear atypia
with multiple multinucleated giant cells. Atypical mitotic
figures were also observed. No intravascular tumor emboli
were noticed. The tumor proliferation was 2 mm from the
edge of resection. The adjacent pancreatic parenchyma was
the seat of chronic pancreatitis lesions. Immunohistology
study demonstrated an expression of anti-cytokeratin anti-
bodies AE1/AE3, negative staining for CD117 and PS100,
and a proliferation rate of 70 %. The giant cells were
mostly positive for CD68 (Figs. 4 and 5). The tumor was
classified as T1N0M0; an adjuvant chemotherapy was
indicated during the meeting of multidisciplinary consulta-
tion, but the patient refused until now any postoperative
treatment. Nine months after surgery, the patient is still
alive and had no recurrence.
Discussion
Undifferentiated pancreatic carcinoma with osteoclast-like
giant cells is a rare malignancy, which accounts for 2–7 %
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of all pancreatic cancers [4, 7]. There are three major subtypes
of undifferentiated pancreatic carcinoma that include giant cell
carcinoma, spindle cell carcinoma, and round cell carcinoma
[4, 8]. The giant cell carcinoma of the pancreas presents three
subtypes: osteoclastic, pleomorphic, and mixed [1, 9]. The
first one like in our case is estimated at 0.2 % of the total
number of pancreatic carcinomas [1]. It was initially reported
in the pancreas by Juan Rosai in 1968 [6]. According to the
literature and similar to pancreatic adenocarcinoma, giant cell
tumors of the pancreas tend to occur in the elderly [1, 4, 9].
The average age of patients is around 60 years, ranging from
28 to 88 years. Males and females appear to be affected in a
fairly equal ratio [3, 10, 11].
Clinically, the reported cases do not show peculiarity com-
pared to conventional pancreatic ductal adenocarcinoma
[11–13]. The main symptoms are abdominal pain and weight
loss. Jaundice occurs if the tumor is located in the head of the
pancreas. A palpable mass may be found in cases of great
tumors. Invasion into adjacent structures is frequent. Nodal or
intra-abdominal metastasis is found in approximately 50 % of
patients at the time of diagnosis [2, 11].
Radiological investigations often show a mixed cystic and
solid tumor with an average size around 6 cm. Most tumors
arise in the head or body of the pancreas [3, 12].
The differential diagnosis of UPC-OGCs includes cystic
lesions like mucinous cystadenomas or cystadenocarcinomas,
pancreatic pseudocysts, pseudopapillary tumors, and also sol-
id pancreatic tumors like ductal pancreatic carcinomas. Solid
tumors may be homogenous on computed tomographic imag-
ing; however, they can also be very inhomogeneous, as focal
hemorrhage or necrosis is frequently found [3, 12, 13].
At the time of diagnosis, more than 80 % of tumors are
already larger than 5 cm and 50 % even larger than 10 cm. In
more than 50 cases, in which tumor size was documented, only
three neoplasias measured less than 3 cm [3]. The tumor size in
our case is 2.5 cm, and this shows the early character of diag-
nosis and treatmentmotivated by chronic pancreatitis symptoms.
Fig. 1 Ultrasound: hypoechogenous, nodular formation in the pancreatic
body
Fig. 2 Computed tomography: limited tissue mass in the pancreatic
body, measuring 2.1×1.5 cm
Fig. 3 Surgical specimen: corporeo-caudal pancreatectomy
Fig. 4 Presence of osteoclast-like giant cells (magnification of ×40)
J Gastrointest Canc (2014) 45 (Suppl 1):S96–S98 S97
Histologically, UPC-OGCs are composed of two distinct
cell types: OGCs and mononuclear cells. Mononuclear cells
originating from epithelium constitute the tumor itself, while
OGCs appear to be a paraneoplastic product of this rare
malignant tumor [2].
More recent molecular studies have demonstrated the pres-
ence of K-ras mutations in the mononuclear cells, suggesting
that they comprise the neoplastic component of UPC-OGCs
and that they may arise from intraductal epithelial precursors
[5]. The frequency of K-ras mutation appears to be higher in
pancreatic carcinoma. More than 93 % of these K-ras muta-
tions are located in codon 12, demonstrating the very high
specificity of K-ras gene mutation for pancreatic carcinoma.
These findings suggest that the K-ras oncogene plays a critical
role in the oncogenesis of UPC-OGCs [2, 12].
As reported in our patient, tumor cells possess cell surface
markers and a histologic appearance consistent with an epi-
thelial cell type [14].
Concerning the treatment, it is recommended to follow
protocols established for ductal pancreatic adenocarcinoma.
In fact, only complete tumor resection may prolong survival
[1, 12–14].
A clear understanding of the clinical behavior of UPC-
OGCs is limited, given the small number of reported cases.
The overall prognosis for these tumors seems to be slightly
more favorable than for pancreatic ductal adenocarcinoma. A
literature review by Shiozawa et al. consisting of 32 cases of
UPC-OGCs, found the mean survival postdiagnosis or post-
surgical resection to be 20.4 months [4, 5, 15].
In conclusion, undifferentiated pancreatic carcinoma with
osteoclast-like giant cells is a rare entity described in a few case
reports. These tumors tend to be large, with a heterogeneous
echotexture. The diagnosis is generally made on surgical spec-
imen, and the prognosis is poor.
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Fig. 5 Marking of tumor cells with anti-cytokeratin antibody
(magnification of ×40)
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